An open-label study of the effect of PEGASYS [peginterferon alfa-2a] on sustained virologic response in patients with chronic hepatitis C receiving ribavirin combination therapy.
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2010
At a glance
- Drugs Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 04 Jun 2010 Additional trial locations (Bosnia and Herzegovina, Czech Republic, Slovakia) identified as reported by Roche record.
- 23 Feb 2010 Status changed from recruiting to completed as reported by Roche record.
- 20 Jun 2006 New trial record.